Fuji Pharma News

Fuji Pharma: Succession of manufacturing and sales approval for 3 products from Mitsubishi Tanabe Pharma to Fuji Pharmaceutical

Jan 29 01:00 ET

Fuji Pharma: Notice of FSN-013 manufacturing and sales approval application in Japan

Oct 18, 2023 02:00 ET

Fuji Pharma: Notice of obtaining approval for manufacture and sale of biosuccessors (biosimilars) of ustekinumab (genetically modified) preparations

Sep 25, 2023 02:00 ET

Fuji Pharma: Notice of an exclusive negotiation rights agreement regarding development and commercialization within Japan for “PH80,” which is currently being developed in the field of women's health

Sep 5, 2023 19:30 ET

Fuji Pharma: Notice of acquisition of manufacturing and marketing approval for drugs jointly developed with Lotus

Aug 15, 2023 02:00 ET

Fuji Pharma: Succession of manufacturing and sales approval for the sustainable male hormone preparation “Testinone Depot for Muscle Injection”

Jul 18, 2023 02:00 ET

Fuji Pharma: Announcement of the launch of our first new supplement brand “LAFILL” for physicians and the launch of the nutritional supplement “Folic Acid+Kestos”

May 10, 2023 02:00 ET

Fuji Pharma: Announcement of the sale of “Nextstellis” in Thailand and the holding of a commemorative lecture

May 8, 2023 02:00 ET

Fuji Pharma: Independent Officer Notification Form

Apr 25, 2023 04:30 ET

Fuji Pharma: Notice regarding the resignation of an outside director

Apr 20, 2023 20:00 ET

Fuji Pharma: Articles of association 2022-12-21

Dec 22, 2022 23:18 ET

Fuji Pharma: Notice of independent director

Nov 30, 2022 03:00 ET

Fuji Pharma Co Ltd: Inheritance of manufacturing and sales approval for four products from Japanese Pharmaceutical to Fuji Pharmaceutical Industry

Dec 28, 2021 02:00 ET

Fuji Pharma Co Ltd: Notice of the new listing of the natural progesterone preparation "Avminol"

Nov 29, 2021 01:00 ET

Fuji Pharma Co Ltd: On the reduction of the amount of Capital Reserve

Nov 11, 2021 04:00 ET

Fuji Pharma Co Ltd: Notice on domestic Business Cooperation of Cervical Canal curing Agent "10 mg for Plopez vagina"

Nov 4, 2021 02:15 ET

Fuji Pharma Co Ltd: Notice of Thailand OLIC Company applying for Import Development products (FSN-013)

Nov 2, 2021 04:00 ET

Fuji Pharma Co Ltd: Notice on the application for the selection of "gold market" in the division of new markets

Sep 16, 2021 05:30 ET

Fuji Pharma Co Ltd: Notice on the decision on additional stock acquisitions in the stock remuneration system

Aug 5, 2021 04:00 ET

Fuji Pharma Co Ltd: In order to build a cooperative system in the field of infertility treatment, Fuji Pharmaceutical Industry and Cellular Source signed a contract for career cooperation.

Apr 1, 2021 03:30 ET